Addictions, Drug & Alcohol Institute
Addictions, Drug & Alcohol Institute > ADAI Publications

ADAI Publications

1331 publications found

  1. Whiteside LK, Lovett K, Nye E, Engstrom A, Hall J, Field C, Haegerty P, Palinkas LA, McGovern M, Banta-Green CJ, Zatzick D. Emergency department longitudinal integrated care (EDLINC) study: Protocol for a pragmatic effectiveness randomized clinical trial. Contemporary Clinical Trials 2026 (in press). [doi: 10.1016/j.cct.2026.108400] PMID: 42419503
  2. Carlini BH, Kellum LB, Garrett SB, Williams JR. Cannabis-related problems, adverse events, clinical experiences and barriers to intervening: Perspectives of health care providers in Washington State. Substance Use & Addiction Journal 2026;47(3):852-863. [doi: 10.1177/29767342261426116] PMID: 41910114
  3. Janson S, Newman A, Banta-Green CJ, Glick SN, Tinsley J, Owens MD. Substance use treatment utilization and unmet demand among recently incarcerated syringe services program participants in Washington state. Harm Reduction Journal 2026 (in press). [doi: 10.1186/s12954-026-01512-z]
  4. Gordon AJ, Hatch MA, Kropp FB, Liebschutz JM, Mooney LJ, Cochran G. Twenty-five years of the NIDA clinical trials network and the future of addiction research. Journal of Substance Use & Addiction Research 2026: 210140 (in press). [doi: 10.1016/j.josat.2026.210140] PMID: 42893770
  5. Dawson D, Hall W, Goodwin I, Carlini BH, Lubman DI, Hammond D, Freeman TP, Lorenzetti V. Exploring THC labelling preferences to communicate the strength of cannabis products: Insights from U.S. consumers. International Journal of Drug Policy 2026;147:105076. [doi: 10.1016/j.drugpo.2025.105076] PMID: 41442927
  6. Cioffi C, Baloh J, Brunner M, Cheng H, DiFiore E, Davis AD, Fenstemark C, Fisher S, Finlayson R, Franz B, Franz D, Hosseini MA, Rains AN, Schmidt A, Smith C, Vest N, Hartzler B, CTN Implementation Strategies Workgroup. A scoping review of implementation strategies to reduce stigma toward people who use substances in healthcare settings. Journal of Substance Use and Addition Treatment 2026 (in press). [doi: 10.1016/j.josat.2026.210005] PMID: 42069061
  7. Winstead T, Newman A. Syringe Services Program Participants’ Perceptions, Concerns, and Experiences of Medications for Opioid Use Disorder (MOUD). Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, May 2026
  8. Carlini BH, Williams JR, Garrett SB, Hammond D. People with psychotic disorders are the most vulnerable to cannabis adverse health outcomes: A study in WA State, USA. Community Mental Health Journal 2026;62:889-895. [doi: 10.1007/s10597-025-01579-1]
  9. Newman A, Banta-Green CJ. Safer Smoking Supplies – Use, Engagement, and Association with Decreased Injecting in Washington State. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, June 2026.
  10. Hartzler B, Brunner M, Fokuo JK, Ostacher MJ, Pagano A, Rutkowski BA, Vest RA, Masson CL. There and back again: Continuing efforts via regional partnership to promote workforce awareness of scientific advancements in addiction care. Journal of Substance Use and Addiction Treatment 2026 (in press). [doi: 10.1016/j.josat.2026.209905] PMID: 41554458
  11. Leyde S, Bell C, Harris C, Wan C, Nye E, Simon CB, Hoog J, Kennedy AJ, Hartzler B, Tsui JI, Fockele C. “It’s not a one-size-fits-all”: Patient perspectives on contingency management and community reinforcement approach for methamphetamine use disorder in permanent supportive housing. Journal of Health Care for the Poor and Underserved 2026;37(2):705-722. [doi: 10.1353/hpu.2026.a992138] PMID: 42290360
  12. Hartzler B, Peng L, Cooke A, Kunkel L, Stack E, Leahy J, Cook R, Hildebran C, Hoffman K, Verbeck J, Nugent M, Leichtling G, Smith Payne K, McIlveen JW, Korthuis PT. Reason to expand the contingency management workforce: Coaching-to-criterion results for addiction professionals and peer specialists. Substance Use & Addiction Journal 2026;47(2):541-548. [doi: 10.1177/29767342251363007] PMID: 40908764
  13. Iacobelli NP, Estrella L, Owens MD, Bhatraju EP, Gojic AJ, Kennedy D, Chander G, Tsui JI. “You’re doing it because your freedom is on the line”: a qualitative study exploring how people who use opioids and methamphetamine navigate legal involvement and carceral treatment for substance use disorder. Harm Reduction Journal 2026; 23, 30. [doi: 10.1186/s12954-025-01378-7] PMID: 41547813
  14. Salinsky LM, Diaz KC, Fox JL, Panh SM, Ferguson SM. Fentanyl, methamphetamine and polysubstance use differentially affect locomotor sensitisation and social behaviour in rats: Psychedelic treatment reverses social deficits. Addiction Biology 2026;31(3):e70132. [doi: 10.1111/adb.70132]
  15. Peng L, Stack E, Cooke A, Hartzler B, Cook R, Leichtling G, Hildebran C, Leahy J, Smith Payne K, Kunkel L, Hoffman K, Korthuis PT. Centering peers in design and training for a peer-delivered contingency management program for self-identified harm reduction and treatment goals. Harm Reduction Journal 2025;22(suppl 1):72. [doi: 10.1186/s12954-025-01213-z] PMID: 40329274 PMCID: PMC12057027
  16. Ball A, Winstead T, Singh S, Floyd A, Banta-Green C. Adolescent and young adult access to opioid use disorder care. Pediatrics 2025;156(1):e2024070224. [doi: 10.1542/peds.2024-070224] PMID: 40499923
  17. Orozco K, Laschober TC, Tross S, Ertl MM, Paschen-Wolff MM, Nelson CM, Lancaster C, Hatch MA. Future pandemic preparedness: conceptualizing vaccine willingness in drug-using populations during COVID-19 in Southeastern U.S. cities. Journal of HIV/AIDS & Social Services 2025 (in press). [doi: 10.1080/15381501.2025.2591675]
  18. Perkins T, Lee B, Mackin J, Donovan D, Rushing SC, Caughlan C, Gchachu Kakuska A, Walker L. Healing of the Canoe: Preliminary suicide prevention outcomes among participating and non-participating youth. Prevention Science 2025;26:740-750. [doi: 10.1007/s11121-025-01806-x] PMID: 40289054
  19. Petersky S, Banta-Green C. Perceptions of Substance Use in Permanent Supportive Housing: Results from the 2024 WA State PerCH Staff Survey. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, March 2025, 10p.
  20. Paschen-Wolff MM, Tross S, Nelson CM, Hatch MA, Meche D, Ertl MM, Wright L, Laschober TC. Factors associated with PrEP awareness and use among men who have sex with men who use drugs in the Southern United States. AIDS Care 2025;37(1):21-32. [doi: 10.1080/09540121.2024.2438923] PMID: 39651544
  21. Owens MD, Adwell A, Singh S, Osilla K, Tweedy M, Tsui J. “All I want is the best for my brother”: Interest in a Community Reinforcement and Family Training (CRAFT)-based group intervention among concerned significant others of individuals on office-based medications for opioid use disorder. BMC Psychiatry 2025;25:748. [doi: 10.1186/s12888-025-07132-4] PMID: 40745287 PMCID: PMC12312360
  22. Hatch MA, Ertl M, Closs D, Keeshin S, Feinberg J, Orozco K, Tross S. HIV prevention in syringe service programs since the start of COVID-19: Where do we go from here? Current HIV/AIDS Reports 2025;22(1):13. [doi: 10.1007/s11904-024-00721-0] PMID: 39812953 PMCID: PMC12640190
  23. Paschen-Wolff MM, Laschober TC, Spector AY, Ertl MM, Nelson CM, Hatch MA, Lancaster C, Wright L, Tross S. “PrEP is always on the table”: Mixed methods study of provider willingness to refer/link clients to PrEP in community sexual health and drug use-related programs. Journal of HIV/AIDS & Social Services 2025 (in press). [doi: 10.1080/15381501.2025.2545265]
  24. Bhat A, Curran MC, Lohr MJ, Smith H, Blanchard B, Stoner SA, Grant T, Grote N. Integrating a brief behavioral intervention into case management for mothers with perinatal substance use disorder: Nonrandomized pilot feasibility study. JMIR Formative Research 2025;9:e75132. [doi: 10.2196/75132] PMID: 41468592 PMCID: PMC12753098
  25. Becker SJ, Janssen T, Souza T, Hartzler B, Rash CJ, DiClemente-Bosco K, Garner BR. Project MIMIC (Maximizing Implementation of Motivational Incentives in Clinics): Results of a 28-site cluster-randomized type 3 hybrid trial. Implementation Science 2025;21(1):9. [doi: 10.1186/s13012-025-01473-0] PMID: 41361474 PMCID: PMC12870086
  26. Jha C, Donovan DM. Harm reduction without supportive policing: Experiences of drug users in Nepal. Journal of Social, Behavioral, and Health Sciences 2025;19:1-17. [doi: 10.5590/JSBHS.2025.19.1678]
  27. Tross S, Laschober TC, Paschen-Wolff M, Ertl M, Nelson CM, Wright L, Lancaster C, Feaster DJ, Monger M, Toal P, Fegley JP, Meche D, Hankey C, Woodhouse C, Spector A, Dresser L, Moran L, Jelstrom E, Haynes L, Shoptaw S, Hatch MA. Willingness to use oral and long-acting injectable PrEP in substance-using men who have sex with men (SU-MSM) in high HIV incidence Southern U.S. cities: A NIDA Clinical Trials Network study. AIDS and Behavior 2025;29(4):1192-1204. [doi: 10.1007/s10461-024-04594-7]
  28. Owens, MD. Evaluation of the City of Seattle Ordinance 126896 on Controlled Substances: Final Report [to the Seattle Office of Inspector General]. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, December 2025.
  29. Siebert SL, Owens MD, Folk JB, Moore KE. Criminal justice staff’s professional quality of life and interactions with justice-involved individuals: The moderating role of stigma. Deviant Behavior 2025;46(6):803-819. [doi: 10.1080/01639625.2024.2372419] PMID: 40519513
  30. Kellum LB, Carlini BH, Garrett S. Assessing Engagement in Cannabis Policy: A Survey of Washington State Elected Officials. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, May 2025
  31. Hunnicut-Ferguson K, Stoner SA, Kable JA, Grant TM, Coles CD. Substance use and mental health symptoms in adults with prenatal alcohol exposure. Neurotoxicology Teratology 2025;109:107436. [doi: 10.1016/j.ntt.2025.107436] PMID: 40032207
  32. Garrett SB, Williams J, Carlini BH, Hammond D. Cannabis consumer patterns, adverse events, and cannabis risk beliefs: A latent profile analysis in WA State. Drug and Alcohol Dependence 2025;273:112728. [doi: 10.1016/j.drugalcdep.2025.112728]
  33. Hartzler B, Doig M, Cooke A, Kunkel L, Peng L, Stack E, Smith Payne K, McIlveen J, Korthuis PT. Training addiction professionals and peers to deliver contingency management via a coaching-to-criterion process: Results of a non-inferiority analysis. Substance Use & Addiction Journal 2025 (in press).
  34. Moore M, Oscadal M. Starting buprenorphine in outpatient settings using a high-dose approach. Journal for Nurse Practitioners 2025;21(1):105260 [doi: 10.1016/j.nurpra.2024.105260]
  35. Newman A, Winstead T, Layman L. “I think one enhances the other”: Use of harm reduction and drug treatment among participants of syringe services programs. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, June 2025
  36. Zinsli KA, Banta-Green CJ, Whiteside LK, Hood J, Kingston S, Tinsley J, Moreno C, Glick SN. Trends and correlates of naloxone possession and use among people who inject drugs in Seattle, Washington. International Journal of Drug Policy 2025;144(Part 1):104272. [doi: 10.1016/j.drugpo.2023.104272] PMID: 38057247
  37. Sladky M, Banta-Green C. Kratom & 7-OH: What do we know about use, safety, and overdose risk? Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, April 2024, updated August 2025.
  38. Paschen-Wolff MM, Campbell ANC, Vasquez A, Kessler J, Jansen K, Arnatt CP, Rosa C, Hebden HM, Radin S, Stately A, Shaw J, Kennedy F, Matthews AG, Venner KL. Conducting an implementation intervention study with American Indian and Alaska native communities: Methodological considerations. Contemporary Clinical Trials 2025:107992. [doi: 10.1016/j.cct.2025.107992] PMID: 40544955
  39. Reiman A, Lessin B. Harm Reduction Approaches with Adolescents Who Use Substances. Routledge, 2025, 172p.
  40. Roll J, Barbosa-Leiker C, Carlini B, Fuchs R, McDonell M, Stella N, Riordan DG, Dyedov R, Ellioff K, Reid S. Cannabis Research in Washington State: A Report for the Washington State Department of Commerce. Seattle, WA: Washington State Academy of Sciences, January 2025, 24 p.
  41. Dillard DA, Hebert LE, Dirks LG, Shaw JL, Trinidad SB, Lillie K, Donovan DM, Burke W, Ludman EJ. Attitudes about alcohol misuse among Alaska Native people in a Tribal health care system. Journal of Addiction Medicine 2025 (in press). [doi: 10.1097/ADM.0000000000001564] PMID: 40928084
  42. Le MH, Laschober TC, Tross S, Paschen-Wolff M, Ertl MM, Wright L, Hatch MA. Attitudes toward and experience with naloxone among people who use drugs in the Southeastern United States. International Journal of Drug Policy 2025;139:10479. [doi: 10.1016/j.drugpo.2025.104769] PMID: 40073718
  43. Cooke A, Stack E, Peng L, Cook R, Hartzler B, Leichtling G, Hildebran C, Leahy JM, Payne KS, Kunkel LE, Hoffman K, Korthuis PT. The peers expanding engagement in stimulant harm reduction with contingency management study: A protocol paper. Addiction Science & Clinical Practice 2025;20:48. [doi: 10.1186/s13722-025-00577-8] PMID: 40495203 PMCID: PMC12150483
  44. Simon CB, Hus C, Prado MG, West II, Kwun CGC, LeMaster JW, Hatch MA, Tong ST, Stephens KA. Examining removal of federal waiver restrictions to prescribing buprenorphine in primary care. Journal of the American Board of Family Medicine 2025;38(3):752-756. [doi: 10.3122/jabfm.2024.240453R1] PMID: 41115754
  45. Lovett K, Zatzick D, Palnikas LA, Engstrom A, Nye E, Field C, McGovern M, Parrish C, Banta-Green CJ, Whiteside LK. Adapting to the fentanyl epidemic: Rapid qualitative observations and derived clinical and research implications from the Emergency Department Longitudinal Integrated Care (ED-LINC) randomized clinical trial. Psychiatry 2025;88(4):333-350. [doi: 10.1080/00332747.2025.2472429] PMID: 40100166
  46. ADAI, Research with Expert Advisors on Drug Use (READU), Owens M. The Community-Law Enforcement Aligning in Response to Substance use (CLEARS) Project. Summary of Process Evaluation Findings. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, June 2025, 28 p.
  47. Ertl MM, Woodhouse C, Meche D, Forrest DW, Fegley J, Paschen-Wolff M, Laschober TC, Hatch MA, Nelson CM, Wright L, Tross S. Using structural modeling to examine barriers and facilitators of HIV pre-exposure prophylaxis willingness and length of use in men who have sex with men who use substances in eight Southern U.S. cities. AIDS Patient Care and STDS 2025;39(6):245-256. [doi: 10.1089/apc.2025.0036] PMID: 40401366 PMCID: PMC12172640
  48. Lancaster C, Laschober TC, Nelson CM, Hatch MA, Paschen-Wolff MM, Ertl MM, Wright L, Tross S. Predicting willingness to use MOUD: An application of the theory of reasoned action and theory of planned-behavior. Journal of Drug Issues 2025 (in press). [doi: 10.1177/00220426251395179]
  49. Winstead T, Singh S, Floyd A, Banta-Green C. Contingency Management for Methamphetamine Use: Qualitative Interviews at Harm Reduction Programs. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, March 2024
  50. Green TC, Silcox J, Boliver D, Gray M, Floyd AS, Irwin AN, Hansen RN, Hartung DM, Bratberg J. Pharmacy staff-reported adaptations to naloxone provision and over-the-counter (OTC) syringe sales during the COVID-19 pandemic: Experiences across multiple states and 2 pharmacy chains. Journal of the American Pharmacists Association 2024;64(1):71-78. [doi: 10.1016/j.japh.2023.10.014] PMID: 37863398 PMCID: PMC11014459